Spiroindolone KAE609 for Falciparum and Vivax Malaria | Zendy

Nicholas J. White | Zendy; Sasithon Pukrittayakamee | Zendy; Aung Pyae Phyo | Zendy; Ronnatrai Rueangweerayut | Zendy; François Nosten | Zendy; Podjanee Jittamala | Zendy; Atthanee Jeeyapant | Zendy; Jay Prakash Jain | Zendy; Gilbert Lefèvre | Zendy; Ruobing Li | Zendy; Baldur Magnusson | Zendy; Thierry T. Diagana | Zendy; F. Joel Leong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Spiroindolone KAE609 for Falciparum and Vivax Malaria

Author(s) -

Nicholas J. White,

Sasithon Pukrittayakamee,

Aung Pyae Phyo,

Ronnatrai Rueangweerayut,

François Nosten,

Podjanee Jittamala,

Atthanee Jeeyapant,

Jay Prakash Jain,

Gilbert Lefèvre,

Ruobing Li,

Baldur Magnusson,

Thierry T. Diagana,

F. Joel Leong

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1315860

Subject(s) - interquartile range , malaria , medicine , plasmodium falciparum , artesunate , adverse effect , plasmodium vivax , primaquine , immunology , chloroquine

KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synthetic antimalarial spiroindolone analogue with potent, dose-dependent antimalarial activity against asexual and sexual stages of Plasmodium falciparum.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research